263 related articles for article (PubMed ID: 26256875)
1. [TET2 as a gatekeeper for hematologic malignancies].
Muto H; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of TET2 in hematologic malignancies.
Chiba S
Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
[TBL] [Abstract][Full Text] [Related]
3. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Nakajima H; Kunimoto H
Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies.
Li W; Xu L
Oncol Res Treat; 2019; 42(6):309-318. PubMed ID: 31055566
[TBL] [Abstract][Full Text] [Related]
5. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
6. [TET2 gene in hematological diseases].
Li S; Wang XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):836-41. PubMed ID: 24989305
[TBL] [Abstract][Full Text] [Related]
7. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
8. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M
Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851
[TBL] [Abstract][Full Text] [Related]
9. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
[TBL] [Abstract][Full Text] [Related]
10. Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.
Joshi K; Zhang L; Breslin S J P; Kini AR; Zhang J
J Exp Clin Cancer Res; 2022 Oct; 41(1):294. PubMed ID: 36203205
[TBL] [Abstract][Full Text] [Related]
11. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
[TBL] [Abstract][Full Text] [Related]
12. The TET2 interactors and their links to hematological malignancies.
Pan F; Weeks O; Yang FC; Xu M
IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
[TBL] [Abstract][Full Text] [Related]
13. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.
Ko M; Bandukwala HS; An J; Lamperti ED; Thompson EC; Hastie R; Tsangaratou A; Rajewsky K; Koralov SB; Rao A
Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14566-71. PubMed ID: 21873190
[TBL] [Abstract][Full Text] [Related]
14. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
Li R; Xu MJ; Yang FC; Zhou Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):583-588. PubMed ID: 27825418
[TBL] [Abstract][Full Text] [Related]
15. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
[TBL] [Abstract][Full Text] [Related]
16. [Functional analysis of TET2 using a knockdown mouse model].
Shide K; Kameda T; Shimoda K
Rinsho Ketsueki; 2015 Jun; 56(6):657-65. PubMed ID: 26256876
[TBL] [Abstract][Full Text] [Related]
17. TET2 in Normal and Malignant Hematopoiesis.
Bowman RL; Levine RL
Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28242787
[TBL] [Abstract][Full Text] [Related]
18. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
19. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.
Song SJ; Ito K; Ala U; Kats L; Webster K; Sun SM; Jongen-Lavrencic M; Manova-Todorova K; Teruya-Feldstein J; Avigan DE; Delwel R; Pandolfi PP
Cell Stem Cell; 2013 Jul; 13(1):87-101. PubMed ID: 23827711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]